Simon Benita |
Simon Benita is a Professor at The Hebrew University of Jerusalem, where he received his Ph.D. in Pharmacy in 1980. His research is focused on polymeric nano- and microparticulate drug delivery systems aimed at improving the therapeutic performance of active ingredients.
Prof. Benita supervises a group of 38 M.Sc., 29 Ph.D. students, and 19 post-doctoral students in pharmaceutical sciences.
He has published 160 research articles and 20 book chapters, has edited or co-edited 5 books and has been issued 38 patents and patent applications.
Prof. Benita received The Hebrew University’s Kaye Innovation Award in 2000, 2005 and again in 2014. He is a Fellow of the American Association of Pharmaceutical Scientists (AAPS).
He is the Founder of Novagali Pharma, a company that received the “91 d’or” Award in 2009 from the French Business Confederation, as well as the Siemens “Health Award”. Frost & Sullivan recognized Novagali Pharma for Innovation in Ophthalmic Therapies and granted it the 2009 Best Practices Award. Novagali was acquired by Santen Japan in 2012.
Other companies founded by Prof. Benita include MacroBea (2011) for the topical administration of nanoparticles for cosmetic applications; and BioNanoSim (BNS) (2015) which focuses on innovative nano-carriers as the solution of choice for enhanced drug delivery to improve therapeutic performance.
Prof. Benita has received awards in Israel and abroad including the Israel Controlled Release Society Chapter Prize for Outstanding Achievements in Controlled Release in September 2012; and the Chevalier dans l’Ordre National du Mérite (Knight in National Order of Merit) from the government of France in May 2012.
He served as the Director of the Institute for Drug Research and Head of the School of Pharmacy, Faculty of Medicine at The Hebrew University of Jerusalem from 2010 to 2014.